C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly EBITDA Margin of 451.64% for Q1 2026, down 4871.0% year-over-year from 9.47% in Q1 2025, and down 114.96% quarter-over-quarter from 210.1% in Q4 2025.
Powered by 
Analysis
C4 Therapeutics (CCCC) EBITDA Margin (2019 - 2026) Analysis & Trends
C4 Therapeutics' EBITDA Margin history runs 8 years deep, the most recent figure standing at 451.64% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 4871.0% year-over-year to 451.64%; the TTM figure through Mar 2026 stood at 326.56% (down 3358.0% YoY), while the FY2025 annual figure was 320.53%, up 1561.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 451.64%, down from 210.1% in the prior quarter.
- The five-year high for EBITDA Margin was 178.59% in Q2 2024, with the low at 1410.21% in Q2 2023.
- The 5-year median for EBITDA Margin is 440.99% (2025), against an average of 598.03%.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin plunged 126575 bps in 2022, then surged 123162 bps in 2024.
- C4 Therapeutics' EBITDA Margin stood at 1341.73% in 2022, then rose by 14 bps to 1147.72% in 2023, then soared by 37 bps to 728.39% in 2024, then jumped by 71 bps to 210.1% in 2025, then plunged by 115 bps to 451.64% in 2026.
- Business Quant data shows CCCC's EBITDA Margin at 451.64% in Q1 2026, 210.1% in Q4 2025, and 306.43% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | C4 Therapeutics | 492.73 Mn | 239.06 Mn | - | -397.88% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -397.88% |
| Mar 31, 2026 | -451.64% |
| Dec 31, 2025 | -210.10% |
| Sep 30, 2025 | -306.43% |
| Jun 30, 2025 | -440.99% |
| Mar 31, 2025 | -402.93% |
| Dec 31, 2024 | -728.39% |
| Sep 30, 2024 | -183.86% |
| Jun 30, 2024 | -178.59% |
| Mar 31, 2024 | -1,060.18% |
| Dec 31, 2023 | -1,147.72% |
| Sep 30, 2023 | -251.16% |
| Jun 30, 2023 | -1,410.21% |
| Mar 31, 2023 | -963.77% |
| Dec 31, 2022 | -1,341.73% |
| Sep 30, 2022 | -481.02% |
| Jun 30, 2022 | -197.95% |
| Mar 31, 2022 | -409.84% |
| Dec 31, 2021 | -75.98% |
| Sep 30, 2021 | -285.34% |